Agenus Inc. Aktie News

LEXINGTON, Mass.--(BUSINESS WIRE)-- #CancerCare--Agenus Inc. (Nasdaq: AGEN) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab (BOT/BAL) combination achieved a two-year survival rate of 42% along with a now more mature 21-month median overall survival (OS) in an expanded cohort of 123 patients with microsatellite-stable (MSS) metastatic colorectal canc...

LEXINGTON, Mass. & SAN FRANCISCO--(BUSINESS WIRE)-- #aiinbiotech--Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology.

LEXINGTON, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN) a leader in immuno-oncology innovation and Noetik, a leader in AI-driven spatial and multimodal biology, today announced a research collaboration to develop predictive biomarkers of response to Agenus' lead clinical stage immuno-oncology (IO) combination, botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as “Zydus,” designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensil...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented new translational data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study demonstrates that botensilimab-based therapy induces a robust and persistent T cell immune response in microsatellite stable (MSS), or mismatch repair proficient (pMMR), metastatic co...

I remain cautiously optimistic about Agenus, driven by BOT/BAL's strong clinical data and cost-reduction efforts, but maintain a speculative 2/5 conviction rating. The BOT/BAL program shows promising efficacy in MSS colorectal cancer, potentially resetting the standard of care and offering a significant commercial opportunity. Agenus's restructuring, asset monetization, and cost cuts aim to ext...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab (BOT/BAL) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress ...